Clinical Protocols for Midazolam Administration in Primary Care Paramedicine

Clinical Intervention Protocols for Midazolam (2026)

The protocol for Midazolam usage by primary care paramedics in 2026 is governed by strict regulatory controls. These controls encompass the entire lifecycle of the drug, including its storage requirements, inventory management, and the specific procedures for its utilization and destruction. This ensuring that the administration of the benzodiazepine is tracked and managed within legal and safety frameworks.

Indications and Conditions for Administration in Convulsions

Midazolam is indicated for patients experiencing specific types of seizures. The primary clinical trigger is the presence of active generalized tonic or tonic-clonic convulsions. For the protocol to be activated, these convulsions must meet one of two criteria: they must be persistent for a duration of $\ge 5\,min$; or they must be repetitive episodes, regardless of the duration of each individual episode, where the patient does not achieve a complete recovery of consciousness between the seizures. Paramedics must verify these conditions before initiating the pharmacological intervention.

Contraindications and Presentation

The primary contraindication for the administration of Midazolam is a known allergy or hypersensitivity to midazolam itself or to any other drug within the benzodiazepine class. In clinical environments, the medication is presented in a concentration of $5\,mg/ml$. To minimize the risk of dosing errors, the protocol strongly recommends using $1\,ml$ vials of this concentration. However, in scenarios where there are supply chain issues or shortages, the use of multidose vials of the same $5\,mg/ml$ concentration is permitted.

Detailed Dosage Parameters

Dosage is strictly categorized by patient weight and age to ensure therapeutic efficacy while minimizing adverse risks. For patients weighing $< 50\,kg$, the initial dose is calculated at $0.2\,mg/kg$, with a maximum absolute limit of $10\,mg/dose$. The subsequent additional dose for this weight group is $0.1\,mg/kg$, with a maximum limit of $5\,mg/dose$. For patients weighing $\ge 50\,kg$, the dosage is age-dependent. Patients $\ge 50\,kg$ and $< 70\,years$ of age receive an initial dose of $10\,mg$ ($2\,ml$) followed by an additional dose of $5\,mg$ ($1\,ml$). For patients $\ge 50\,kg$ who are $\ge 70\,years$ of age, the initial dose is reduced to $5\,mg$ ($1\,ml$) and the additional dose is $2.5\,mg$ ($0.5\,ml$).

Administration Routes and Limitations

The approved routes for administration are Intranasal (IN) and Intramuscular (IM). There are significant restrictions regarding the intranasal route. Midazolam must not be administered via the IN route if the patient is a pediatric case $< 6\,months$ old, or if the patient presents with nasal congestion, epistaxis (nosebleed), or vasoconstriction of the nasal mucosa, as these conditions significantly impair drug absorption through the nasal membranes.

Repetition and Clinical Specifics

A second dose of Midazolam may be administered after an interval of $10\,min$ if the initial clinical conditions (active convulsions) are still present. The protocol strictly limits the total cumulative administration to a maximum of $2$ doses. Special consideration is required if a benzodiazepine anticonvulsant, such as diazepam or midazolam, was administered by a family member or bystander prior to the paramedics' arrival. In such cases, paramedics must ensure a minimum delay of $10\,min$ has elapsed between the pre-arrival dose and the first dose administered by the paramedics. If the seizure activity ceases following treatment but then recurs later, the paramedic should restart the administration sequence beginning with the initial dose.

Adverse Effects and Systemic Impact

Midazolam administration can lead to various adverse effects across multiple biological systems. Central Nervous System (CNS) effects include agitation, amnesia, headache, confusion, CNS depression, dizziness, weakness, hallucinations, sedation, and somnolence. Cardiovascular impacts may manifest as bradycardia, hypertension, hypotension, or tachycardia. Notably, the drug can cause respiratory depression, which requires careful monitoring. Sensory effects such as diplopia (double vision) or blurred vision may occur, and gastrointestinal symptoms like nausea and vomiting are also possible.

Pharmacokinetics and Pharmacodynamics

Midazolam is classified as a benzodiazepine and an anticonvulsant. Its pharmacokinetics vary significantly between the IM and IN routes. The bioavailability for the IM route is $> 90\%$, while the IN route ranges between $40\% \text{ to } 60\%$. The onset of action for the IM route is between $5 \text{ to } 15\,min$, whereas the IN route typically begins to work within $5\,min$. The half-life of the drug is highly variable, ranging from $2 \text{ to } 6\,hours$. The maximum duration of effect is $2 \text{ to } 6\,hours$ for IM administration, but much shorter for the IN route, lasting only $30 \text{ to } 60\,min$. Midazolam undergoes hepatic metabolism, specifically via the $CYP3A4$ enzyme, and is eliminated by the kidneys in the form of conjugates.